EP300 and acute lymphoblastic leukemia: Thus, for example, novel recurrent MEF2D-fusions (BCL9, HNRNPUL1, DAZAP1) and ZNF384 fusions (EP300, EWSR1, TCF3, TAF15, CREBBP) have been described in 6.7% and 7.3% of adults, 3.4% and 3.9% of pediatric patients with B-ALL, respectively [1,105].